Ceryvyn Therapeutics (ASX:CYV), a clinical-stage Australian biopharmaceutical company, has lodged a November 2026 investor information presentation detailing its development program for CYV-101, a first-in-class fusion protein targeting lymphangioleiomyomatosis, a rare progressive lung disease that almost exclusively affects women.
Key Points
- CYV-101 is a first-in-class fusion protein designed to neutralise VEGF-C and VEGF-D, intended to test whether inhibiting this pathway can reduce abnormal lymphatic remodelling in LAM.
- Approximately 5,000 LAM patients are estimated in the US, with recent analysis suggesting up to 250,000 undiagnosed worldwide.
- CYV-101 has not been approved by the Therapeutic Goods Administration, the US Food and Drug Administration, or any other regulatory authority, and its safety and efficacy have not been established.
- The company is led by Executive Chair and CEO Dr Jeremy Levin and guided by a scientific advisory board of global LAM thought leaders.
Focus on Lymphangioleiomyomatosis and CYV-101
According to the filing, Ceryvyn is focused on lymphangioleiomyomatosis, described as a rare, progressive lung disease in which abnormal cells proliferate in the lungs and lymphatics, forming cysts that destroy lung tissue. The company states there is no cure for LAM. CYV-101 is described as a clinical-stage biologic and a first-in-class fusion protein designed to neutralise VEGF-C and VEGF-D. The company intends to test whether inhibiting this pathway can reduce abnormal lymphatic remodelling in LAM patients.
Clinical Development Setting and Program Characteristics
The filing outlines several characteristics of LAM that the company identifies as relevant to its development approach. These include established diagnostic criteria and biomarkers described as supporting patient identification, the existence of specialist centres providing a defined clinical development setting, potential eligibility for orphan-drug incentives, and established patient organisations described as potentially supporting trial awareness and recruitment. The filing also cites significant unmet need in a chronic disease managed through specialist centres.
Company Background and Leadership
The filing describes Ceryvyn Therapeutics as a clinical-stage Australian biopharmaceutical company developing medicines based on advances in human biology for patients with serious disease. The company is described as a product of Australian science and Australian investment. Dr Jeremy Levin serves as Executive Chair and CEO. The presentation, dated November 2026, notes that all dollar amounts referenced are in Australian dollars and that the information presented is unaudited. The filing states it should be read in conjunction with Ceryvyn's other periodic and continuous disclosure filings lodged with the ASX.




Please wait processing your request...